Fluvoxamine (brand name Luvox)

(Trade Names: Luvox and Faverin)

Fluvoxamine was the first non-Tricyclic antidepressant (TCA) drug approved by the U.S. Food and Drug Administration (FDA), specifically for the treatment of OCD, in 1993.

Form: tablets.
Children: The NICE guidelines for treating OCD report that Fluvoxamine has a UK Marketing Authorisation for use in OCD in children 8 years and older (November 2005).
Fluvoxamine has a UK marketing authorisation for treating OCD in children aged 8 years and older.
Adult dose: 50 mg at bedtime, increase gradually in steps of 50 mg up to a maximum of 300 mg/day. If there is no improvement within 10 weeks, it should be reviewed.
Half-life: 15.6 hours
Drug interactions: Monoamine oxidase inhibitors (MAOI) should not be given until at least five weeks after stopping Fluvoxamine. It also interacts with the asthma drugs theophylline and aminophylline.
Withdrawal: Avoid abrupt withdrawal.

Copyright © 2004-2017 OCD-UK.
Charity Registration Number: 1103210
OCD-UK, Marble Hall (Office 5), 80 Nightingale Road, Derby DE24 8BF

OCD-UK is a non-profit making charity and not associated with any other organisation. Medical information is provided for education/information purposes only, you should obtain further advice from your doctor. Any links to external websites have been carefully selected, however we are not responsible for the content of these third party websites.